

References

Acharya et al. (2004): L. Acharya and K. Douglas, An Act to amend the Patent Act and the Food and Drugs Act, LS-474E (Legislative Summary – Bill C-9), 3 mars 2004. www.parl.gc.ca/common/bills_ls.asp?Parl=37&Ses=3&ls=c9

AFP (2001): AIDS activists in Kenya launch campaign for cheap drugs bill, Agence France Press, 28 May 2001. www.aegis.com/NEWS/AFP/2001/AF0105B2.html

Aidslaw (2004): Global access to treatment. Canada's Bill C-9 and the Compulsory Licensing of Pharmaceuticals for Export to Countries in Need, July 2004. www.aidslaw.ca/Maincontent/issues/cts/patent-amend/billC-9flyer300604.pdf

Aidslaw (2004a): Steps forward, backward and sideways; Canada's Bill on exporting generic pharmaceuticals, December 2004. www.aidslaw.ca/Maincontent/otherdocs/Newsletter/vol9no32004/forward-generic.htm#_ednref1

Andrade (2005): J. Andrade in Brasil Agora, 15 julho 2005.

anRs (2003): Economics of AIDS and access to HIV/AIDS care in developing countries. Issues and Challenges (Collection Sciences Sociales et SIDA). Paris: anRs, 2003.

Archimède (2004): L. Archimède, on the Doctor's Daily, 6 July 2004.

Assoumani (2005): M.B. Assoumani, Report on the intellectual property and development meeting (1st April 2005). www.holambecomores.com/public/htmlprint.php?id_article=151

Bern (2005): Conference on Access to pharmaceuticals, Health Right Institute, World Trade Institute, Bern, 18 november 2005. Contact: rachel.liechti@iew.unibe.ch

Bioscience (2005): Asked and answered. Bioscience World, 8 February 2005. www.bioscienceworld.ca

BCIPR (2002): Report of the British Commission on intellectual property rights. London: BCIPR, 2002.

Brady et al. (2004): C. Brady and O. Soos: Sea Island Summit analytical studies; Country objectives for the 2004 Sea Island Summit. Canada, G-8 information center, University of Toronto Library, 30th July 2004.

Bulard (2004): M. Bulard, Enquiry on a health apartheid, Medical Apartheid, Manière de voir, N° 73, February-March 2004, p.65.

Buse et al. (2002): K. Buse and G. Walt, Globalisation and multilateral public-private health partnerships; Issues for health policy, in Lee *et al.* (2002), pp.41-62.

Canada (2004): Canada's Act to amend the Patent Act and the Food and Drugs Act, 3rd Session, 37th Parliament, 52-53 Elizabeth II, 2004. www.parl.gc.ca/37/3/parlbus/chambus/house/bills/government/C-9/C-9_1/90247bE.html

Canada (2004a): The Jean Chrétien Pledge to Africa Act Approved by Parliament, Press Release, Ottawa, 13 mai 2004.

Carroll (2004): A.Carroll (Minister of International Cooperation, Canada), Notes for remarks-Bangkok International AIDS Conference-Bill C-9 Symposium, Bangkok, Thailand, 15 July 2004.

CETIM (2004): The dangers of FTAA and the urgent necessity for an alternative development, Geneva : CETIM, 2004.

CIPIH (2004): OMS Note for the Press, N° 10, 4 avril 2004, Geneva: WHO, 2004.

CIPIH (2004a): WHO announces the membership of the Commission on intellectual property rights, innovation and public health (CIPIH), Geneva: WHO, 2004. www.who.int/intellectualproperty/background/members/en/index.html

CIPIH (2005): Intellectual property rights, innovation and public health; Report of the Secretariat, 22 December 2005, Geneva: WHO, 2005. www.who.int/gb/ebwha/pdf_files/EB117/

CIPIH (2005a): Mee-too drugs: Good or bad?, Third discussion, 2005. www.who.int/intellectualproperty/forum/3rd_discussion/en/

CL (2004): Commons-law; A discussion list on law, culture and technology. [mail.sarai.net/pipermail/commons-law/](mailto:sarai.net/pipermail/commons-law/) et ensuite choisir 2004, october.

Correa (2001): C.Correa, Patent law, TRIPS, and R&D incentives; A Southern perspective, Commission on Macroeconomics and Health, Working Paper WG2:12. Buenos Aires, 2001.

Correa (2002): C.M.Correa, Implications on the Declaration on the TRIPS Agreement and public health adopted at Doha, Economics of health and medicines, N° 12, OS: Geneva, 2002. whqlibdoc.who.int/hq/2002/WHO_EDM_PAR_2002.3_fre.pdf

Correa (2004): C.M.Correa, Implementation of the WTO General Council decision on paragraph 6 of the Doha Declaration on the TRIPS agreement and public health, Health economics and drugs series, no16, Geneva: WHO, 2004.

Demenet (2003): Ph.Demenet, The come back of barefoot doctors, in Medical Apartheid I, N° 73, February-March 2003, pp.57-59.

Doha (2001): the Declaration on the TRIPS Agreement and public health, adopted at Doha (14th November 2001), Appendix 1, in Correa (2002).

Ellen et al. (2003): F.M.Ellen and T.Hoen: TRIPS, pharmaceutical patents and access to essential medicines; Seattle, Doha and beyond. Geneva: WHO, 2003.

e-med (2004): Intellectual property and patents protection, India, 30th November 2004. www.essentialdrugs.org/emed/archive/200411/msg00110.php

Estrategía (2004): Con nueva normativa de salud medicamentos genéricos subirán 25%, entrevue à José Antonio Plubins (Pdg du Laboratorio Bagó), Estrategía, 31 de mayo 2004.www.estrategia.cl/histo/200405/31/ambito/bago.htm

Fassin (2000): D.Fassin, The political stakes of health, Karthala, Paris: Kathala, 2000.

FGC/DB (2005): Letter of the Geneva Cooperation Federation and of the Bern Declaration to Mr Manmohan Singh, Prime Minister of India, 24 February 2005. (copy of this letter available on www.fgc.ch; see also Petite (2005)).

Garrison (2004): Ch.Garrison, Intellectual property rights and vaccines in developing countries (Background paper for a WHO workshop in Geneva, WHO-IVB (2004), Geneva: WHO-IVB, 2004. www.who.int/intellectualproperty/events/en/Background_paper.pdf

Gerster (2000): R.Gerster, How WTO/TRIPS threatens the Indian pharmaceutical industry. TWNOnline, september 2000 (voir aussi MIHR (2005)). (R.Gerster worked as an independent consultant for the Swiss government and several NGO's; he is interested in the problem of patents and intellectual property protection within the framework of North-South relations; he can be contacted at rgerster@active.ch). www.twinside.org.sg/title/twr120h.htm

Guillot (2002): O.Guillot, Market integration in a small federal state (Switzerland); The role of public health, dans Reshaping the TRIPS Agreement concerning public health – Two critical issues. Haochen Sun: WTO Research Center of Zhejiang University, 2002.

Haajer-Ruskamp I (1991): F.M.Haajer-Ruskamp and M.N.G.Dukes, Drugs and Money, the Problem of Cost Containment. Groningen, Stix Publications, 1991.

Healthgap (2005): Changes to India's Patents Act and access to affordable generic medicines after January 1, 2005 (Fact sheet, 2005), (see also MIHR (2005)). www.healthgap.org/press_releases/04/121404_HGAP_FS_INDIA_patent.doc

HUG (2005): Geneva Forum, Towards global access to health, 30 August-1st September 2006, Geneva: Hôpitaux Universitaires de Genève, 2005. www.hcuge.ch/genevahealthforum/ ; contact: act.humanitaire@hcuge.ch

ICTSD (2002): Trade, IP and sustainable development as seen from Africa, ICTSD, Enda, Solagral, 2002.

IUED (1998): Which stakes for Developing Countries? Record of the Switzerland – Third World Annual 1998, int. N°54, Geneva: IUED, 1998.

IUED (2001): Health at the risk of the market; Uncertainty at the dawn of the XXI century, New booklets of IUED, Paris, PUF, 2001.

Jennar (2003): R.-M.Jennar, What is the purpose of the WTO agreement on essential medicines ; A placebo for the poor, Le Courrier, 16 March 2003.

Jennar (2005): R.-M.Jennar, The forgotten file; The patents which kill, 14 November 2005. reseaudesbahuts.lautre.net/article.php3?id_article=168

Keayla (2004): B.K.Keayla, Review of patent legislation of India, Indonesia, Sri Lanka and Thailand; Measures to safeguard public health (voir aussi MIHR (2005)), New Delhi: WHO, 2004.

Keith (2000): M.Keith, Intellectual property rights in the global economy, 2000.

Kremer et al. (2004): M.Kremer and R.Glennester, Strong medicine; Creating incentives for pharmaceutical research on neglected diseases, Princeton, Princeton U.P., 2004.

Krikorian (2005): G.Krikorian, The access to medicines compromised by the bilateral policies reinforcing intellectual property (extract from the book: Pouvoir Savoie, Paris, C & F Editions, 2005).

Kumara (2005): K.Kumara, India adopts WTO patent law with left front support (see also MIHR (2005)), World Socialist Web, 18 April 2005. www.countercurrents.org/gl-kumara180405.htm

Labrin (2003): J.M.Labrin Elgueta, Medicamentos; La trampas del acuerdo entre Chile y Estados Unidos. Una mirada a la apertura neoliberal de Chile, por el economista y director de la revista Economía Crítica y Desarrollo, Claudio Lara Cortés. Diario de la Sociedad Civil, 9 de junio 2003. www.sociedadcivil.cl/nuevodiario/sitio/informaciones/documento.asp?ld=829;labrin@sociedadcivil.cl

Lamoine (1999): B.Lamoine, Panorama of the world pharmaceutical industry, quoted in Pharmaceutical industry, from globalisation to ethics, French Review of Geoeconomics, N° 12, Paris, Winter 1999-2000, p.33.

Lander (2004): E.Lander, Which integration political project for Latin America? Network of information & solidarity with Latin America (RISAL), 2004.

Lanjouw (2005): J.O.Lanjouw, Patents, price controls and access to new drugs; How policy affects global market entry. www.who.int/intellectualproperty/studies/rd_trips/en/

Lee et al. (2002): K.Lee, K.Buse and S.Fustukian (eds.), Health policy in a globalising world, New York, Cambridge (UK) University Press, 2002.

Lewis-Lettington et al. (2004): R.Lewis-Lettington and P.Munyi, Willingness and ability to use TRIPs flexibilities; Kenya case study, DFID Health Systems Resource Centre, September 2004. www.dfidhealthrc.org/shared/publications/Issues_papers/ATM/Lettington2.pdf

Lorelle (2003): V.Lorelle, The neglected diseases of the Third World. *Le Monde*, 26 May 2003.

Mamou (2004): Y.Mamou, Generic medicines do not stop developing, *Le Monde*, 28 Decembrer 2004.

Marquet (2003): I.Marquet, Accessibility to antipaludic medicines in Senegal; effects of the introduction of the association artesunate/amodiaquine, Memoir of DESS in Public Health, University of Orsay – Paris XI, Paris, Ecole Nationale de la Santé Publique, 2003. www.remed.org/memoire_Isabelle_Marquet-v1.rtf

MIHR (2005): Innovation in developing countries to meet health needs; Experiences of Brazil, China, India, and South Africa (an overview report to the CIPIH), Centre for Management of Intellectual Property in Health R&D, April 2005.

Moon (2002): S.Moon, Implementation of the Doha Declaration on the TRIPS Agreement and public health; Technical assistance: how to get it right (Conference report, Geneva, 28 March 2002), Geneva, MSF-CPTOxfam-HAI, 2002. www.haiweb.org/campaign/access/ReportPostDoha.pdf

MSF (2001): Fatal imbalance; The crisis in research and development for drugs for neglected diseases, Geneva: MSF, 2001.

MSF (2002): Untangling the web of price reductions; A pricing guide for the purchase of ARNs for developing countries, Geneva: MSF, 2002.

MSF (2003): DOHA round the bend: Report on the evolution of the TRIPS agreements and the access to medicines, contribution of Médecins Sans Frontières in view of the 5th WTO Ministerial Conference, Cancún, Geneva: MSF, 2003.

MSF (2005): Letters to the President, Prime Minister and National Advisory Council of India, february 2005 (voir aussi MIHR (2005)). This document can be found in Patents (2005).

MSF (2005a): Statement by MSF at the WIPO Inter-sessional intergovernmental development agenda for WIPO (April 2005). This document can be found on the site of CIPIH: www.who.int/intellectualproperty/topics/innovation/innovation/en/index.html

MSF (2005b): The effects of the 2005 TRIPS implementation deadline on access to medicines, February 2005, Geneva: MSF, Campaign for access to essential medicines, 2005. This document can be found on the site of CIPIH: www.who.int/intellectualproperty/submissions/en

MSF (2005c): AIDS, medicines at an affordable price, Geneva: MSF, 4 July 2005.

MSF/HAI (2000): Improving access to essential medicines in East Africa: Patents and prices in a global economy, Rapport de la Conférence sur l'accès aux médicaments des pays de l'Afrique de l'Est aux médicaments essentiels, Nairobi, 15-16 juin 2000, Médecins Sans Frontières et Health Action International, 2000.

Musungu (2005): S.F.Musungu, Rethinking innovation, development and intellectual property in the UN: WIPO and beyond, TRIPS issues papers, N° 5, Ottawa, Quaker International Programme, 19 August 2005. www.qiap.ca/pages/documents/trips53.pdf

Musungu et al. (2003): S.F.Musungu and G.Dutfield, Multilateral agreements and a TRIPS-plus world; The World Intellectual Property Organization (WIPO), Geneva, Quaker United Nations Office, 2003. [www.qiap.ca/documents/wipo\(us\)final.pdf](http://www.qiap.ca/documents/wipo(us)final.pdf)

Musungu et al. (2004): S.F.Musungu, S.Villanueva and R.Blasetti, Utilizing TRIPS flexibilities for public health protection through South-South regional frameworks, Geneva, SouthCentre, 2004.

Musungu et al. (2005): S.F.Musungu and C.Oh The use of flexibilities in TRIPS by developing countries; Can they promote access to medicines? www.who.int/intellectualproperty/studies/musungo-ho.pdf

New (2005): W.New, India's TRIPS compliance effort could be test case. Intellectual Property Watch, 24 March 2005 (voir aussi MIHR (2005)). lists.essential.org/pipermail/a2k/2005-March/000165.html

Niveaux (2002): Development levels of the pharmaceutical industry country by country, Appendix 2, in Correa (2002).

NYT (2005): India's choice (Editorial), New York Times, 18 January 2005. Oliveira *et al.* (2004): M.A.Oliveira, J.A.Zepeda Bermudez, Gabriela Costa Chaves and G.Velásquez, Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health? Bulletin of the WHO, N° 82, November 2004.

OMC (1994): Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS); Appendix 1C of the Marrakech agreement instituting WTO, 15 April 1994, Geneva: WTO, 1994. www.wto.org/french/docs/f/legal_f/27-trips.pdf

OMC (2003): Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and public health; Decision of the General Council of the 30 August 2003. www.wto.org/french/tratop_f/trips_f/implem_para6_f.htm

OMC et al. (2002): TRIPS and public health: position taken on the negotiations deriving from paragraph 6 of the Doha Declaration and the proposals from Switzerland, Swiss Coordination – WTO and Berne Declaration, 2002.

OMS (1991): Evaluation of recent reforms carried out in the financing of health services. Geneva:WHO, 1991.

OMS (1995): Report from the WHO Experts Committee on the national pharmaceutical policies, Action Programme for Essential Medicines, Geneva: WHO, 1995.

OMS (1998): Health reforms and financing of medicines, Health Economics and Medicines, N° 6, Geneva: WHO, 1998.

OMS (2000): Pharmaceutical Strategy of WHO; Action framework for essential medicines and pharmaceutical policy. Geneva: WHO, 2000.

OMS (2001): World Alliance for vaccines and vaccination (GAVI), Aide-mémoire N° 169. Geneva: WHO, March 2001. www.who.int/mediacentre/fractsheets/fs169/fr/

OMS (2001a): Globalisation, TRIPS and access to pharmaceutical products, WHO's Political prospects on medicines, N° 3. Geneva: WHO, 2001.

OMS (2001b): Macroeconomics and health: invest in health for economic development, Geneva: WHO, 2001.

OMS (2002): Selection of essential medicines. WHO's Political prospects on medicines, N° 4. Geneva: WHO, 2002. For the last model list of essential medicines, see: www.who.int/druginformation/vol19num3_2005

OMS (2002a): Implications of the Declaration on the TRIPS Agreement and public health adopted at Doha, Economics of health and medicines, N° 12, Geneva: WHO, 2002.

OMS (2002b): Report on infectious diseases, Geneva: WHO, 2002.

OMS (2002c): WHO Press release, 9 July 2002, Geneva: WHO, 2002. www.who.int/inf/en/pr-2002-58.html

OMS (2003): The United Nations institutions and the generic medicines industry reinforce their collaboration so as to broaden the access to essential medicines. Press release of WHO, 26 February 2003. Geneva: WHO, 2003. www.who.int/mediacentre/news/statements/2003/statement4/fr/

OMS (2004): WHO's Pharmaceutical Strategy; The front line countries, 2004-2007, Geneva: WHO, 2004. The complete report is only available in English: WHO medicines strategy; Countries at the core, 2004-2007. WHO, Geneva 2004.

OMS (2004a): Fair access to essential medicines; Collective action framework, WHO, Political Prospects on medicines, N° 8, Geneva: WHO, 2004.

OMS-IVB (2004): WHO Workshop on intellectual property rights and vaccines in the DC's, Geneva, 19-20 April 2004. Department of Vaccinations, vaccines and biological products, WHO, Geneva, 2004. www.who.int/vaccines-documents/

OMS/OMC (2002): The WTO agreements and public health. Joint study of WHO and WTO, Geneva: WHO/WTO, 2002. www.wto.org/french/res_f/booksp_f/who_wto_f.pdf

ONISIDA/OMS (2004): Status report on the AIDS epidemics, Geneva: ONISIDA/OMS, December 2004.

Oxfam (2004): Socavando el acceso a medicinas; Comparación de cinco TLCs de los Estados Unidos. Una nota técnica, Oxfam, junio 2004.
www.choike.org/documentos/oxfamJulio2004.pdf

Oxfam (2005): Letter to the Prime Minister of India, 15 March 2005. This document can be found in Patents (2005).

Patents (2005): Patent legislation passed March, 2005 (India's Rajya Sabha, Uppen house of parliament). This page enables photocopying a large number of documents: Indian Government documents, NGO documents, UN Agency documents, Statements from Indian pharmaceutical companies and News stories.
www.cptech.org/ip/health/c/india/patents-act-amendments.html

Pécoul (2002): B.Pécoul, Presentation at the Conference on Implementation of the Doha Declaration on the TRIPS Agreement and public health; Technical assistance, how to get it right, in Moon (2002).

Pécoul (2005): B.Pécoul, Restart research and development of medicines against neglected diseases, in Assoumani (2005).

Pei (2004): N.Pei, Canadian Parliament approves legislation to permit exports of patented pharmaceuticals to developing countries, Canadian Pharmaceutical Intellectual Property Newsletter: June 2004

Petite (2003): S.Petite, Research forgets tropical diseases, *Le Courier*, Geneva, 11 February 2003.

Petite (2005): S.Petite, Bye bye generics made in India. *Le Courier*, Geneva, 26 February 2005.

Petite (2005a): S.Petite, WTO reaches an agreement; the WTO members ratified a procedure supposed to facilitate the access of poor countries to generic medicines. *Le Courier*, Geneva, 8 December 2005.

QUNO (2001): The TRIPS Agreement, access to medicines and the WTO Doha Ministerial Conference, Occasional Paper 7, Geneva, Quaker United Nations Office, 2001.

Ramachandran (2003): R.Ramachandran, A patent war in Thailand.
lists.essential.org/pipermail/ip-health/2003-October/005523.html

Ramonet (2003): The sentence of Gro Bruntland is quoted by Ignacio Ramonet in *Le Monde*, 26 November 1999; see also Unequal death in Medical Apartheid, *Manière de voir* N° 73, February-March 2003, p.6.

Ranson et al. (2002): M.K.Ranson, R.Beaglehole, C.M.Correa, Z.Mirza, K.Buse and N.Drager, The public health implications of multilateral trade agreements, in Lee *et al.* (2002), pp.18-40.

Regards (2004): AIDS, the price of life. *Regards*, N° 11, November 2004.

Reinhard (2002): J. Reinhard, TRIPS and public health: position taken on the negotiations deriving from paragraph 6 of the Doha Declaration and the proposals from Switzerland, Lausanne: Berne Declaration, 2002.

Reinhard (2003): J.Reinhard, Price decrease through competition of generics, *Solidaire* (Berne Declaration), N° 170, May 2003.

Reinhard (2003a): J.Reinhard, The Brazilian experience, an example for the South, *Solidaire* (Berne Declaration), N° 170, May 2003; see also MIHR (2005).

Reinhard (2004): J.Reinhard, Vider Doha de sa substance; The TRIPSplus agreements and their effects on access to medicines in developing countries, Lausanne: Berne Declaration, August 2004.

Ridde et al. (2004): V.Ridde et J.-E. Girard, Twelve years after the Bamako Initiative: taking note and political implications for a fair access to health services for African indigents, *Public Health*, vol. 15, N° 1, 2004, Geneva, 2004.
www.pnud.ne/rese/Biblioth%E8que/Ridde02.pdf

Roberts (2004): L.Roberts, Drugs of choice, *Sustainable Times*, May 2004.
www.sustainabletimes.ca/articles/drugs.htm

SAPA-AFP (2001): AIDS activists in Kenya launch campaign for cheap drugs bill. SAPA-AFP, 28 May 2001. new.hst.org.za/news/index.php/20010519

Scherer (2001): F.M.Scherer, Post-Trips options for access to patented medicines in developing countries. Commission on Macroeconomics and Health, Working Paper WG4: 1, Harvard, 2001.

Shiva (2005): V.Shiva, WTO, patents on lifeforms and amendements in India's Patent law, *Znet*, 7 April 2005 (see also MIHR (2005)). This document is on a sustainer page: www.zmag.org/sustainers/ which is now only open to those who have paid a subscription to *z-mag*.

Silva Consuelo (2005): Silva C., Development versus the common wealth of information and intellectual property, in V.Peugeot (ed.), *Pouvoir Savoir*, Paris: C & F Éditions, 2005. www.vecam.org/article.php3?id_article=432

Silva Consuelo (2005a): Silva C., Chile; ADPIC-Plus versus acceso a medicamentos (private communication, 2005).

Smith (2005): A.Smith, A framework for developing a research agenda for diseases disproportionately affecting the poor: The cases of malaria, diabetes, and rotavirus. www.who.int/intellectualproperty/studies/Developing/es/

Tankoano (2002): A.Tankoano, Parallel imports and non voluntary licences in the new patents law of the OAPI Member States (Organisation Africaine de la Propriété Intellectuelle).
www.ictsd.org/dlogue/2002-07-30/docs/TANKOANO.pdf

Third World (2003): Third World Network, Manual on good practices in public-health-sensitive policy measures and patent laws, Penang, Third World Network, Mai 2003. www.twinside.org.sg

Thorpe (2002): P.Thorpe, Study of the implementation of the TRIPS Agreement by developing countries, Commissions on Intellectual Property Rights, Study paper N° 7, Geneva: WTO, 2002.

Towse (2005): A.Towse, A review of the IP and non-IP incentives for R&D for diseases of poverty (a final report for the WHO CIPIH, 28 April 2005), London, OHE Consulting (Division of the Office of Health Economics of the English government), 2005. This document can be found on the site of CIPIH: www.who.int/intellectualproperty/studies/en/

Trouiller et al. (2002): P.Trouiller, P.Oliario, E.Torreele, J.Orbinski, R.Laing and N.Ford, Drug development for neglected diseases; A deficient market and a public health policy failure, *The Lancet*, June 22 2002. www.dndi.org/cms/public_html/images/article/228/lancet%20r&d.pdf

UNDP(2002): Report on human development, New York: UNDP, 2002.
Velásquez (2003): G.Velásquez, Hold-up on medicines. *Le Monde Diplomatique*, August 2003, pp.26-27.

Velásquez et al. (1999): G.Velásquez and P.Boulet, Globalisation and access to medicines; Prospects on the WTO TRIPS Agreement. Health economics and medicines, N° 7 (revised version), Geneva: WHO, 1999 (also in English).

Walder (2003): P.Walder, Los medicamentos; El otro negocio de la salud, Punto Final N° 553, 26 de setembre 2003. www.puntofinal.cl/553/medicamentos.htm

Walker (2001): S.Walker, The TRIPS Agreement, sustainable development and the public interest, Cambridge, World Conservation Union, 2001.

WHO (1996): Evolving public-private roles in the pharmaceutical sector, Action Programme on Essential Drugs, Geneva: WHO, 1996.

WHO (2002): Framework for action in essential drug policy, 2002-2003. Geneva: WHO, 2002.

WHO (2002a): Network for monitoring the impact of globalization and TRIPS on access to medicines, Meeting Report, 19-21 February 2001, Bangkok, Thailand. Geneva: WHO, 2002.

WHO (2004): Equitable access to essential medicines: A framework for collective action, Policy Perspectives on Medicines, N°8, Geneva: WHO, 2004.

WHO (2004a): Determining the patent status of essential medicines in developing countries (Health economics and drugs series, N° 17), Geneva: WHO, 2004.

WHO (2005): Intensified control of tropical diseases; Neglect—a key feature of neglected diseases, Geneva: WHO, 2005. www.who.int/neglected_diseases/en/

WHO (2005a): Intellectual property protection; Impact on public health, in WHO Drug Information, vol.19, N°3, 2005, pp.236-241. www.who.int/druginformation/vol19num3_2005/DI19-3.pdf

WHO/EB (2003): Essential drugs and medicines policy, 111th session of the WHO Executive Board, January, 2003.

WIPO (2004): Preliminary briefing to WHO CIPIH; Prospective WIPO inputs, Geneva: WIPO, 5 April 2004. www.who.int/intellectualproperty/submissions/en

Zibechi (2005): R.Zibechi, Regional integration after the failure of the Free Trade Area of the Americas, Information & solidarity network with Latin America (RISAL), 16 March 2005.